Berlin, 24 November 2022

Resolve Biosciences secures $71 million in Series B financing

Resolve Biosciences GmbH secures $71 million in a Series B financing to accelerate commercial expansion and meet global demand for its Molecular Cartography™ platform. The funding follows the launch of the technology delivering highest-resolution view of subcellular, single-molecule, spatial biology. The latest round of financing was led by Patient Square Capital and included participation from EDBI, PS Capital, Alafi Capital and NRW.BANK, as well as other existing investors. The company has now raised more than $100 million.


Prof. Dr. Hans-Eric Rasmussen-Bonne, LL.M, and Andreas Michael, LL.M., provided comprehensive contractual advice to the investor NRW.BANK. The law firm Weitnauer regularly represents NRW.BANK in financing rounds.



About NRW.Venture.

NRW.Venture is the venture fund of NRW.BANK. With this fund, the development bank for North Rhine-Westphalia supports innovative and technology-driven start-ups with a concrete connection to NRW in the development and marketing as well as the rapid expansion of their business model. The fund invests up to ten million euros of equity over several financing rounds - together with private-sector investors - and has been active in the market for more than 15 years. The total volume of NRW.Venture is 250 million euros.



Advisor NRW.BANK

Prof. Dr. Hans-Eric Rasmussen-Bonne, LL.M. (Lead, VC, Corporate/Berlin)

Andreas Michael, LL.M. (VC, Corporate/Berlin), Partner